# US 2026/0124258 A1 · Probiotic compositions for improving human health and athletic performance

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0124258 A1
- Document ID: US20260124258A1
- Status: Published application
- Kind: A1
- Application number: 19/232,716
- Filed: 2025-06-09
- Published: 2026-05-07
- Earliest claimed: 2020-03-13
- Assignees: Fitbiomics Inc.
- Applicants: FitBiomics, Inc.
- Inventors: Jonathan SCHEIMAN
- Web page: https://patentgrep.com/patent/US20260124258A1

## CPC

- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 35/745: Bifidobacteria
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C12N 1/20: Bacteria; Culture media therefor
- C12N 1/205: Bacterial isolates
- A61K 2035/115: {Probiotics}
- C12R 2001/01: Bacteria or Actinomycetales {; using bacteria or Actinomycetales}
- C12R 2001/225: Lactobacillus
- C12R 2001/23: Lactobacillus acidophilus
- C12R 2001/25: Lactobacillus plantarum
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

The disclosure provides novel microorganisms, such as Lactobacillus sp., Bifidobacterium sp., and Veillonella sp., and compositions thereof for improving athletic performance, enhancing exercise endurance, improving physical recovery from exercise, and reducing inflammation in a subject in need thereof.

## Claims

### Claim 1

A composition comprising one or more of the following strains:
(a) an isolated and purified Lactobacillus plantarum, comprising: a 16S rRNA gene comprising a nucleic acid sequence comprising at least one variable region (VR) selected from the group consisting of: VR1, VR2, VR3, VR4, VR5, VR6, VR7, VR8, VR9, and any combination thereof, wherein (i) VR1 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 2; (ii) VR2 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 3; (iii) VR3 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 4; (iv) VR4 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 5; (v) VR5 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 6; (vi) VR6 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 7; (vii) VR7 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 8; (viii) VR8 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 9; and (ix) VR9 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 10;
(b) an isolated and purified Lactobacillus rhamnosus, comprising: a 16S rRNA gene comprising a nucleic acid sequence comprising at least one variable region (VR) selected from the group consisting of VR1, VR2, VR3, VR4, VR5, VR6, VR7, VR8, VR9, and any combination thereof, wherein (i) VR1 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 22; (ii) VR2 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 23; (iii) VR3 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 24; (iv) VR4 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 25; (v) VR5 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 26; (vi) VR6 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 27; (vii) VR7 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 28; (viii) VR8 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 29; and (ix) VR9 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 30;
(c) an isolated and purified Lactobacillus acidophilus, comprising: a 16S rRNA gene comprising a nucleic acid sequence comprising at least one variable region (VR) selected from the group consisting of: VR1, VR2, VR3, VR4, VR5, VR6, VR7, VR8, VR9, and any combination thereof, wherein (i) VR1 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 42; (ii) VR2 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 43; (iii) VR3 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 44; (iv) VR4 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 45; (v) VR5 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 46; (vi) VR6 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 47; (vii) VR7 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 48; (viii) VR8 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 49; and (ix) VR9 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 50;
(d) an isolated and purified Lactobacillus paracasei, comprising: a 16S rRNA gene comprising a nucleic acid sequence comprising at least one variable region (VR) selected from the group consisting of: VR1, VR2, VR3, VR4, VR5, VR6, VR7, VR8, VR9, and any combination thereof, wherein (i) VR1 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 62 or SEQ ID NO: 182; (ii) VR2 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 63 or SEQ ID NO: 183; (iii) VR3 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 64 or SEQ ID NO: 184; (iv) VR4 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 65 or SEQ ID NO: 185; (v) VR5 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 66 or SEQ ID NO: 186; (vi) VR6 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 67 or SEQ ID NO: 187; (vii) VR7 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 68 or SEQ ID NO: 188; (viii) VR8 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 69 or SEQ ID NO: 189; and (ix) VR9 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 70 or SEQ ID NO: 190;
(e) an isolated and purified Bifidobacterium longum, comprising: a 16S rRNA gene comprising a nucleic acid sequence comprising at least one variable region (VR) selected from the group consisting of: VR1, VR2, VR3, VR4, VR5, VR6, VR7, VR8, VR9, and any combination thereof, wherein (i) VR1 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 82, SEQ ID NO: 202, or SEQ ID NO: 222; (ii) VR2 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 83, SEQ ID NO: 203, or SEQ ID NO: 223; (iii) VR3 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 84, SEQ ID NO: 204, or SEQ ID NO: 224; (iv) VR4 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 85, SEQ ID NO: 205, or SEQ ID NO: 225; (v) VR5 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 86, SEQ ID NO: 206, or SEQ ID NO: 226; (vi) VR6 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 87, SEQ ID NO: 207, or SEQ ID NO: 227; (vii) VR7 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 88, SEQ ID NO: 208, or SEQ ID NO: 228; (viii) VR8 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 89, SEQ ID NO: 209, or SEQ ID NO: 229; and (ix) VR9 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 90, SEQ ID NO: 210, or SEQ ID NO: 230; and
(f) an isolated and purified Bifidobacterium animalis lactis, comprising: a 16S rRNA gene comprising a nucleic acid sequence comprising at least one variable region (VR) selected from the group consisting of: VR1, VR2, VR3, VR4, VR5, VR6, VR7, VR8, VR9, and any combination thereof, wherein (i) VR1 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 102; (ii) VR2 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 103; (iii) VR3 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 104; (iv) VR4 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 105; (v) VR5 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 106; (vi) VR6 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 107; (vii) VR7 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 108; (viii) VR8 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 109; and (ix) VR9 comprises a nucleic acid sequence with at least 95% sequence identity to SEQ ID NO: 110.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the composition comprises the isolated and purified Lactobacillus plantarum, comprising a 16S rRNA gene comprising a Lactobacillus plantarum of claim 1, wherein the nucleic acid sequence comprising at least one constant region (CR) selected from the group consisting of: CR1, CR2, CR3, CR4, CR5, CR6, CR7, CR8, CR9, CR10, and any combination thereof, wherein (i) CR1 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 11; (ii) CR2 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 12; (iii) CR3 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 13; (iv) CR4 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 14; (v) CR5 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 15; (vi) CR6 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 16; (vii) CR7 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 17; (viii) CR8 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 18; (ix) CR9 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 19; and (x) CR10 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 20.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the composition comprises the isolated and purified Lactobacillus plantarum, comprising: a 16S rRNA gene comprising a nucleic acid sequence with at least 97% sequence identity to SEQ ID NO: 1.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the composition comprises:
(a) an isolated and purified Lactobacillus plantarum having deposit accession number 202103009, or a strain having all of the identifying characteristics of Lactobacillus plantarum 202103009, or a mutant thereof;
(b) an isolated and purified Lactobacillus rhamnosus having deposit accession number 202103010, or a strain having all of the identifying characteristics of Lactobacillus rhamnosus 202103010, or a mutant thereof;
(c) an isolated and purified Lactobacillus acidophilus having deposit accession number 202103008, or a strain having all of the identifying characteristics of Lactobacillus acidophilus 202103008, or a mutant thereof;
(d) an isolated and purified Lactobacillus paracasei having deposit accession number 202103012 or 202103018, or a strain having all of the identifying characteristics of Lactobacillus paracasei 202103012 or 202103018, or a mutant thereof;
(e) an isolated and purified Bifidobacterium longum having deposit accession number 202103013, 202103014, 202103015, or a strain having all of the identifying characteristics of Bifidobacterium longum 202103013, 202103014, 202103015, or a mutant thereof; and/or
(f) an isolated and purified Bifidobacterium animalis lactis having deposit accession number 202103016, 202103017, or 202103019, or a strain having all of the identifying characteristics of Bifidobacterium animalis lactis 202103016, 202103017, or 202103019, or a mutant thereof.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The composition of claim 1, wherein the composition comprises the isolated and purified Lactobacillus rhamnosus, comprising a 16S rRNA gene comprising a nucleic acid sequence comprising at least one constant region (CR) selected from the group consisting of: CR1, CR2, CR3, CR4, CR5, CR6, CR7, CR8, CR9, CR10, and any combination thereof, wherein (i) CR1 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 31; (ii) CR2 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 32; (iii) CR3 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 33; (iv) CR4 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 34; (v) CR5 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 35; (vi) CR6 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 36; (vii) CR7 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 37; (viii) CR8 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 38; (ix) CR9 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 39; and (x) CR10 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 40.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the composition comprises the isolated and purified Lactobacillus rhamnosus, comprising: a 16S rRNA gene comprising a nucleic acid sequence with at least 97% sequence identity to SEQ ID NO: 21.

### Claim at position 8

-9. (canceled)

### Claim 10 (depends on 1)

The composition of claim 1, wherein the composition comprises the isolated and purified Lactobacillus acidophilus, comprising a 16S rRNA gene comprising a nucleic acid sequence comprising at least one constant region (CR) selected from the group consisting of CR1, CR2, CR3, CR4, CR5, CR6, CR7, CR8, CR9, CR10 and any combination thereof, wherein (i) CR1 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 51; (ii) CR2 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 52; (iii) CR3 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 53; (iv) CR4 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 54; (v) CR5 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 55; (vi) CR6 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 56; (vii) CR7 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 57; (viii) CR8 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 58; (ix) CR9 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 59; and (x) CR10 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 60.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the composition comprises the isolated and purified Lactobacillus acidophilus, comprising: a 16S rRNA gene comprising a nucleic acid sequence with at least 97% sequence identity to SEQ ID NO: 41.

### Claim at position 11

-13. (canceled)

### Claim 14 (depends on 1)

The composition of claim 1, wherein the composition comprises the isolated and purified Lactobacillus paracasei, comprising a 16S rRNA gene comprising a nucleic acid sequence comprising at least one constant region (CR) selected from the group consisting of CR1, CR2, CR3, CR4, CR5, CR6, CR7, CR8, CR9, CR10 and any combination thereof, wherein (i) CR1 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 71 or SEQ ID NO: 191; (ii) CR2 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 72 or SEQ ID NO: 192; (iii) CR3 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 73 or SEQ ID NO: 193; (iv) CR4 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 74 or SEQ ID NO: 194; (v) CR5 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 75 or SEQ ID NO: 195; (vi) CR6 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 76 or SEQ ID NO: 196; (vii) CR7 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 77 or SEQ ID NO: 197; (viii) CR8 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 78 or SEQ ID NO: 198; (ix) CR9 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 79 or SEQ ID NO: 199; and (x) CR10 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 80 or SEQ ID NO: 200.

### Claim 15 (depends on 1)

The composition of claim 1, wherein the composition comprises the isolated and purified Lactobacillus paracasei, comprising: a 16S rRNA gene comprising a nucleic acid sequence with at least 97% sequence identity to SEQ ID NO: 61 or SEQ ID NO: 181.

### Claim at position 14

-17. (canceled)

### Claim 18 (depends on 1, 17)

The composition of claim 1, wherein the composition comprises the isolated and purified Bifidobacterium longum, comprising a 16S rRNA gene comprising a Bifidobacterium longum of claim 17, wherein the nucleic acid sequence comprising at least one constant region (CR) selected from the group consisting of CR1, CR2, CR3, CR4, CR5, CR6, CR7, CR8, CR9, CR10 and any combination thereof, wherein (i) CR1 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 91, SEQ ID NO: 211, or SEQ ID NO: 231; (ii) CR2 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 92, SEQ ID NO: 212, or SEQ ID NO: 232; (iii) CR3 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 93, SEQ ID NO: 213, or SEQ ID NO: 233; (iv) CR4 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 94, SEQ ID NO: 214, or SEQ ID NO: 234; (v) CR5 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 95, SEQ ID NO: 215, or SEQ ID NO: 235; (vi) CR6 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 96, SEQ ID NO: 216, or SEQ ID NO: 236; (vii) CR7 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 97, SEQ ID NO: 217, or SEQ ID NO: 237; (viii) CR8 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 98, SEQ ID NO: 218, or SEQ ID NO: 238; (ix) CR9 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 99, SEQ ID NO: 219, or SEQ ID NO: 239; and (x) CR10 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 100, SEQ ID NO: 220, or SEQ ID NO: 240.

### Claim 19 (depends on 1)

The composition of claim 1, wherein the composition comprises the isolated and purified Bifidobacterium longum, comprising: a 16S rRNA gene comprising a nucleic acid sequence with at least 97% sequence identity to SEQ ID NO: 81, SEQ ID NO: 201, or SEQ ID NO: 221.

### Claim at position 17

-21. (canceled)

### Claim 22 (depends on 1)

The composition of claim 1, wherein the composition comprises the isolated and purified Bifidobacterium animalis lactis, comprising a 16S rRNA gene comprising a nucleic acid sequence comprising at least one constant region (CR) selected from the group consisting of CR1, CR2, CR3, CR4, CR5, CR6, CR7, CR8, CR9, CR10 and any combination thereof, wherein (i) CR1 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 111; (ii) CR2 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 112; (iii) CR3 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 113; (iv) CR4 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 114; (v) CR5 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 115; (vi) CR6 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 116; (vii) CR7 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 117; (viii) CR8 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 118; (ix) CR9 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 119; and (x) CR10 comprises a nucleic acid sequence with at least 80% sequence identity to SEQ ID NO: 120.

### Claim 23 (depends on 1)

The composition of claim 1, wherein the composition comprises the isolated and purified Bifidobacterium animalis lactis, comprising: a 16S rRNA gene comprising a nucleic acid sequence with at least 97% sequence identity to SEQ ID NO: 101.

### Claim at position 20

-32. (canceled)

### Claim 33

A composition comprising:
(a) a purified Lactobacillus plantarum comprising a 16S rRNA nucleic acid sequence that is at least 97% identical to SEQ ID NO: 1;
(b) a purified Lactobacillus rhamnosus comprising a 16S rRNA nucleic acid sequence that is at least 97% identical to SEQ ID NO: 21;
(c) a purified Lactobacillus acidophilus comprising a 16S rRNA nucleic acid sequence that is at least 97% identical to SEQ ID NO: 41;
(d) a purified Lactobacillus paracasei comprising a 16S rRNA nucleic acid sequence that is at least 97% identical to SEQ ID NO: 61 or SEQ ID NO: 181;
(e) a purified Bifidobacterium longum comprising a 16S rRNA nucleic acid sequence that is at least 97% identical to SEQ ID NO: 81, SEQ ID NO: 201, or SEQ ID NO: 221;
(f) a purified Bifidobacterium animalis lactis comprising a 16S rRNA nucleic acid sequence that is at least 97% identical to SEQ ID NO: 101;
(g) a purified Veillonella dispar comprising a 16S rRNA nucleic acid sequence that is at least 97% identical to SEQ ID NO: 121;
(h) a purified Veillonella parvula comprising a 16S rRNA nucleic acid sequence that is at least 97% identical to SEQ ID NO: 141; and/or
(i) a purified Veillonella atypica comprising a 16S rRNA nucleic acid sequence that is at least 97% identical to SEQ ID NO: 161.

### Claim at position 22

-35. (canceled)

### Claim 36 (depends on 33)

A The composition of claim 33, comprising:
(a) a purified Lactobacillus plantarum having the deposit accession number 202103009;
(b) a purified Lactobacillus rhamnosus having the deposit accession number 202103010;
(c) a purified Lactobacillus acidophilus having the deposit accession number 202103008;
(d) a purified Lactobacillus paracasei having the deposit accession number 202103012 or 202103018;
(e) a purified Bifidobacterium longum having the deposit accession number 202103013, 202103014, or 202103015;
(f) a purified Bifidobacterium animalis lactis having the deposit accession number 202103016, 202103017, or 202103019;
(g) a purified Veillonella dispar having the deposit accession number PTA-126861;
(h) a purified Veillonella parvula having the deposit accession number PTA-126859; and/or
(i) a purified Veillonella atypica having the deposit accession number PTA-126860.

### Claim 37 (depends on 1)

The composition of claim 1, wherein the composition is administered at a dose that alters the microbiome, enhances exercise endurance, improves athletic performance, increases muscle mass, increases muscular strength, prevents the loss of muscle mass, enhances physical recovery, improves digestion, improves metabolism, increases immunity, reduces inflammation, and/or improves sleep quality in a subject in need thereof.

### Claim 38 (depends on 1)

The composition of claim 1, wherein the composition is a food composition, a beverage composition, or a dietary supplement composition.

### Claim 39 (depends on 1)

A method of:
(a) altering the microbiome of a subject in need thereof;
(b) enhancing exercise endurance in a subject in need thereof;
(c) improving athletic performance in a subject in need thereof;
(d) enhancing recovery from physical exercise in a subject in need thereof;
(e) reducing inflammation in a subject in need thereof;
(f) increasing muscle mass and/or muscle strength in a subject in need thereof;
(g) preventing loss of muscle mass in a subject in need thereof; and/or
(h) improving sleep quality in a subject in need thereof;
wherein the method comprises administering an effective dose of the composition of claim 1 to the subject.

### Claim 40 (depends on 1)

A method of reducing the level of lactic acid and/or lactates or increasing the level of propionic acid, propionates, acetic acid and/or acetates in blood of a subject in need thereof comprising administering an effective dose of the composition of claim 1 to the subject.

### Claim at position 28

-49. (canceled)

### Claim 50 (depends on 39)

The method of claim 39, wherein the administration is via oral, enteric, gastrointestinal, or rectal route.

### Claim 51 (depends on 39)

The method of claim 39, wherein the subject is a human subject.

### Claim 52 (depends on 39)

The method of claim 39, wherein the dose is in the range of about 104 CFU to about 1016 CFU.

### Claim 53 (depends on 39)

The method of claim 39, wherein the dose is in the range of about 109 CFU to about 1011 CFU.

### Claim 54 (depends on 39)

The method of claim 39, wherein the dose is in the range of about 5×109 CFU to about 1010 CFU.

### Claim 55 (depends on 39)

The method of claim 39, wherein the dose is about 3.5×1010 CFU.

### Claim 56 (depends on 39)

The method of claim 39, wherein the composition is administered orally to the subject.

### Claim 57 (depends on 39)

The method of claim 39, wherein the composition is a food composition, a beverage composition, or a dietary supplement composition.

### Claim 58

A composition comprising:
(a) a purified Lactobacillus plantarum comprising a 16S rRNA nucleic acid sequence that is at least 97% identical to SEQ ID NO: 1;
(b) a purified Lactobacillus rhamnosus comprising a 16S rRNA nucleic acid sequence that is at least 97% identical to SEQ ID NO: 21; and/or
(c) a purified Lactobacillus acidophilus comprising a 16S rRNA nucleic acid sequence that is at least 97% identical to SEQ ID NO: 41.

### Claim 59 (depends on 58)

The composition of claim 58:
(a) a purified Lactobacillus plantarum comprising a 16S rRNA nucleic acid sequence that is at least 98% identical to SEQ ID NO: 1;
(b) a purified Lactobacillus rhamnosus comprising a 16S rRNA nucleic acid sequence that is at least 98% identical to SEQ ID NO: 21; and/or
(c) a purified Lactobacillus acidophilus comprising a 16S rRNA nucleic acid sequence that is at least 98% identical to SEQ ID NO: 41.

### Claim 60 (depends on 58)

The composition of claim 58:
(a) a purified Lactobacillus plantarum comprising a 16S rRNA nucleic acid sequence that is at least 99% identical to SEQ ID NO: 1;
(b) a purified Lactobacillus rhamnosus comprising a 16S rRNA nucleic acid sequence that is at least 99% identical to SEQ ID NO: 21; and/or
(c) a purified Lactobacillus acidophilus comprising a 16S rRNA nucleic acid sequence that is at least 99% identical to SEQ ID NO: 41.

### Claim 61 (depends on 58)

The composition of claim 58:
(a) a purified Lactobacillus plantarum comprising a 16S rRNA nucleic acid sequence of SEQ ID NO: 1;
(b) a purified Lactobacillus rhamnosus comprising a 16S rRNA nucleic acid sequence of SEQ ID NO: 21; and/or
(c) a purified Lactobacillus acidophilus comprising a 16S rRNA nucleic acid sequence of SEQ ID NO: 41.
